Drug Trial Radar · NCT04562090
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
Last checked: Nov 20, 2026Latest source record: Nov 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
249
Actual
Start
Jan 6, 2021
Primary completion
Mar 17, 2022
Study completion Mar 30, 2022
Sponsor
- Lead sponsor
- Astellas Pharma China, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Sep 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of overactive bladder (OAB) in Chinese participants. This study also evaluated the safety of mirabegron for the treatment of OAB in Chinese participants, evaluated other efficacy variables of mirabegron for the treatment of OAB and explored different mirabegron starting doses.
Conditions
- Urge Incontinence
- Overactive Bladder (OAB)
Interventions
mirabegronDrug
Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline (CFB) to the End of 12-Week Treatment Period in Mean Number of Micturition/24 Hours in Mirabegron 50 mg GroupTime frame: Baseline, week 12
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Site CN86001
Beijing, China
Site CN86004
Beijing, China
Site CN86014
Beijing, China
Site CN86010
Chengdu, China
Site CN86009
Guangzhou, China
Site CN86018
Guangzhou, China
Site CN86003
Lanzhou, China
Site CN86013
Shanghai, China
Site CN86002
Suzhou, China
Site CN86021
Taiyuan, China
Site CN86011
Wuhan, China
Site CN86022
Wuxi, China
Site CN86012
Xi'an, China
Site CN86007
Zhengzhou, China
Site CN86020
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.